

Date: April 22, 2026

To,
BSE Limited,
20th Floor, P.J. Towers,
Dalal Street,
Mumbai - 400001.
BSE Scrip Code: 544449

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051
NSE Scrip Symbol: ANTHEM

Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam

Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR”), we wish to inform you that the Board of Directors of Anthem Biosciences Limited ("Company") at its meeting held on Wednesday, April 22, 2026 which commenced at 2:30 P.M (IST) and concluded at 3.32 P.M (IST) have inter-alia, approved the following matters:

1. Appointment of the Statutory Auditors of the Company

In terms of Clause 7 of Para A Part A Schedule III of Regulation 30 of SEBI LODR, this is to inform that the existing Statutory Auditors of the Company, K.P. Rao & Co., Chartered Accountants, shall complete their current term upon the conclusion of the twentieth AGM proposed to be held in the financial year 2026-2027.

Hence, the Board of Directors on the recommendation of the Audit Committee has approved and recommended to the Shareholders, the appointment of M/s. S. R. Batliboi & Associates LLP, Chartered Accountants (FRN: 101049W/E300004) as the Statutory Auditors of the Company for a period of 5 consecutive years from the conclusion of the Annual General Meeting to be held in the financial year 2026-2027 till the conclusion of the Annual General Meeting to be held in the financial year 2031-2032.

The details as required under the SEBI Mater Circular on SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 dated January 30, 2026 are enclosed as **Annexure A**

2. Approval of Upside Sharing Arrangement under Regulation 26(6) of SEBI LODR

In terms of Regulation 26(6) of the SEBI (LODR) Regulations, 2015 and other applicable provisions of Companies Act, 2013, this is to inform that the Board of Directors of the Company has approved an

existing Upside Sharing Arrangement and recommended the same for approval of the public shareholders by way of an ordinary resolution, with the related parties abstaining from voting.

The aforesaid arrangement is set out in the Shareholders' Agreement dated March 01, 2021 (as amended pursuant to the Waiver-cum-Amendment Agreement dated December 30, 2024) ("SHA"). The SHA and the Waiver-cum-Amendment Agreement are available on the Company's website at <https://anthembio.com/investors/>. The salient terms of this arrangement have been disclosed in the Prospectus dated July 16, 2025 (Page 237 under "**History and Certain Corporate Matters**"). The arrangement pertains to an understanding between the Promoters and Viridity Tone LLP ("Investor") for sharing of returns arising from the Investor's post-listing divestment of equity shares of the Company.

The SHA read with the Waiver Cum Amendment Agreement provides that in the event the Investor sells all or any part of its shareholding post listing of the equity shares, which results in the Investor receiving a return on its original investment, which is in excess of, the higher of (a) 25% of the amount invested by the Investor, or (b) 2 times the amount invested by the Investor, such excess amount, hereinafter referred to as the "Upside", the Investor will share with Mr. Ajay Bhardwaj, Mr. Ganesh Sambasivam and Mr. K Ravindra Chandrappa ("Upside Promoters") an amount equal to such percentage of the Upside as may be mutually agreed basis the abovementioned thresholds between the Upside Promoters and the Investor, in cash and / or in such manner as may be agreed in writing, subject to applicable law and for the avoidance of doubt, it is hereby clarified that the Upside share amount shall not be satisfied by way of transfer of any Shares.

Pursuant to the aforesaid, the Investor has divested 20,313,795 equity shares of the Company on March 09, 2026, resulting in a net realization of INR 13,170 million, out of which INR 1,276.83 million is payable to the Upside Promoters in accordance with the terms of the arrangement. Appropriate disclosures in this regard will be included in the notice of the twentieth Annual General Meeting.

The above intimation is also available on the Company's website at <https://anthembio.com/investors/>

We request you to kindly take the same on record.

Thanking you,

Yours truly,

For Anthem Biosciences Limited

Divya Prasad
Company Secretary & Compliance Officer
Membership No: A41438

ANNEXURE A

Sl. No	Particulars	Responses
1.	Reason for change	K.P. Rao & Co., Chartered Accountants (ICAI FRN: 003135S) will continue as the Statutory Auditors of the Company until the conclusion of the 20th Annual General Meeting to be held in the financial year 2026–2027. Further, based on the recommendation of the Audit Committee, the Board of Directors has approved in the meeting held today, subject to the approval of the Members, the appointment of M/s. S. R. Batliboi & Associates LLP, Chartered Accountants (FRN: 101049W/E300004), as the Statutory Auditors of the Company.
2.	Date of appointment & Term of Appointment	Based on the recommendation of the Audit Committee, the Board of Directors, at its meeting held today, has approved the appointment of M/s. S. R. Batliboi & Associates LLP, Chartered Accountants (FRN: 101049W/E300004), as the Statutory Auditors of the Company, subject to the approval of the Members for a period of 5 consecutive years from the conclusion of the Annual General Meeting to be held in the financial year 2026-2027 till the conclusion of the Annual General Meeting to be held in the financial year 2031-2032.
3.	Brief Profile	M/s. S. R. Batliboi & Associates LLP (“the Firm/SRB”), a limited liability partnership firm incorporated in India, in 1949 with its registered office in Kolkata and has offices across key cities in India. The firm is registered with the Institute of Chartered Accountants of India (“ICAI”) with (ICAI Firm Registration No. 101049W/E300004). The S.R. Batliboi & Associates network of firms includes – M/s. S.R. Batliboi & Co LLP, M/s. S.R. Batliboi & Associates LLP, M/s. S R B C & CO LLP, M/s. S.V. Ghatalia & Associates LLP. All the network firms including the Firm are primarily engaged in providing audit and assurance services

		to its clients. They along-with its network firms audit several large listed and private companies across diverse market segments including Industrial, Infrastructure, Consumer Products, Financial Services, Technology, Media and Entertainment, Telecommunications and Professional Services.
4.	Disclosure of relationships between directors	Not Applicable